TABLE 1.

Drug susceptibilities of 69 Mycobacterium abscessus complex isolates

Antimicrobial agent	No. (%) of isolates with drug susceptibility			MIC (μg/mL)
	Sa	Ia	Ra	S	I	R
Imipenemb		3 (4.41)	65 (95.59)	≤4	8–16	≥32
Linezolidb	5 (7.35)	2 (2.94)	61 (89.71)	≤8	16	≥32
SXTb	1 (1.47)		67 (98.53)	≤2/38		≥4/76
Cefoxitinb	3 (4.41)	34 (50.00)	31 (45.59)	≤16	32–64	≥128
Tobramycinb		6 (8.82)	62 (91.18)	≤2	4	≥8
Doxycyclineb	3 (4.41)	3 (4.41)	62 (91.18)	≤1	2–4	≥8
Amikacinb	44 (64.71)	22 (32.35)	2 (2.94)	≤16	32	≥64
Ciprofloxacinb		2 (2.94)	66 (97.06)	≤1	2	≥4
Moxifloxacinb	1 (1.47)		67 (98.53)	≤1	2	≥4
Clarithromycinb	13 (19.12)		55 (80.88)	≤2	4	≥8
AMCc			68 (100)	≤16	32	≥64
Cefepimec			68 (100)	≤8	16	≥32
Ceftriaxonec		1 (1.47)	67 (98.53)	≤16	32	≥64
Minocyclinec	1 (1.47)	3 (4.41)	64 (94.12)	≤1	2–4	≥8
Tigecyclinec	67 (98.53)		1 (1.47)	≤4		>4

^aS, susceptible; I, intermediate; R, resistant.

^bFirst-line antimicrobials against MABC isolates.

^cSecondary antimicrobials against MABC isolates. Previously reported interpretation criteria are used in this study (49).